Literature DB >> 34785486

Beyond the bundle: Clinical controversies in the management of sepsis in emergency medicine patients.

Kavita Krishnan1, Travis B Wassermann1, Patrick Tednes2, Veronica Bonderski2, Megan A Rech3.   

Abstract

Sepsis is a condition characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The emergency department (ED) serves as a crucial entry point for patients presenting with sepsis. Given the heterogeneous presentation and high mortality rate associated with sepsis and septic shock, several clinical controversies have emerged in the management of sepsis. These include the use of novel therapeutic agents like angiotensin II, hydrocortisone, ascorbic acid, thiamine ("HAT") therapy, and levosimendan, Additionally, controversies with current treatments in vasopressor dosing, and the use of and balanced or unbalanced crystalloid are crucial to consider. The purpose of this review is to discuss clinical controversies in the management of septic patients, including the use of novel medications and dosing strategies, to assist providers in appropriately determining what treatment strategy is best suited for patients.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin II; ED; Hydrocortisone; Sepsis; Thiamine; Treatment

Mesh:

Substances:

Year:  2021        PMID: 34785486     DOI: 10.1016/j.ajem.2021.11.003

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

Review 1.  Therapeutic Strategies Targeting Mitochondrial Dysfunction in Sepsis-induced Cardiomyopathy.

Authors:  Oluwabukunmi Modupe Salami; Olive Habimana; Jin-Fu Peng; Guang-Hui Yi
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-15       Impact factor: 3.727

2.  Evaluating the potency of blood long noncoding RNA PVT1 as candidate biomarker reflecting inflammation, multiple organ dysfunction, and mortality risk in sepsis patients.

Authors:  Jing Chen; Haibo Ren; Bo Liu
Journal:  J Clin Lab Anal       Date:  2022-02-04       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.